This week, we dive into the newly launched medical device regulatory reliance program between Malaysia and Thailand. This landmark initiative promises to fast-track market access, but navigating the nuances is critical for success. We explore the opportunities for MedTech innovators and uncover the hidden challenges beneath the surface of this new streamlined pathway.

Imagine your Class C device, already approved in Malaysia, is poised for quick entry into Thailand under the new program. Suddenly, your application stalls for weeks due to a subtle difference in clinical evidence requirements that wasn't immediately apparent. This is the critical gap between promise and reality that we dissect in this episode.

Key Takeaways:

- What specific device classes are eligible for the Malaysia-Thailand reliance program?

- How does an "abridged review" differ from a full submission, and what documents are still required?

- Why might your existing labeling and Instructions for Use cause unexpected delays in Thailand?

- What are the separate post-market surveillance obligations you must maintain in each country?

- Could this pilot program be the blueprint for a unified ASEAN medical device market?

- How do you prepare a technical dossier that satisfies both regulators simultaneously?

- What is the most common mistake companies make when using this new pathway?

Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative in over 30 markets, develop efficient regulatory strategies, and use AI to manage technical dossiers. Whether you're a startup or a multinational, we provide scalable solutions to help you navigate complex environments. Contact Pure Global at [email protected] or visit us at https://pureglobal.com/.